Posts tagged controlling HIV
New Anti-HIV Drugs
10 years ago
by ADMIN
in HIV Therapy
New Anti-HIV Drugs: Research in Stopping AIDS
In December of 2013, researchers at the University of Minnesota published some very striking and uniformly positive findings in the fight against HIV. They discovered several compounds that uniquely targeted HIV cells. These compounds – ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2’-C-methylcytidine – stop HIV replication by blocking DNA synthesis. This is achieved by causing the HIV cells to drop their DNA load before they are ready to and not within blood cells. The compounds also cause the HIV cells to mutate so rapidly that the cells essentially mutate themselves into extinction. The findings were a surprise to most of the anti-HIV research community, because the compounds in question were not on anyone’s radar. In fact, they seemed to have no potential for stopping HIV. Another major benefit to these compounds is the low cost of synthesizing them into new anti-HIV drugs. This is always an important factor, as it lessens the burden for the future prevention and treatment of HIV.
In fact, this is what has been occurring over the past year. The new anti-HIV drugs, which were synthesized version of these compounds, have been introduced in tangent with currently approved HIV medications. So far, the reports have been positive. Although the drugs do not fully eradicate HIV from an infected person’s system, the new drugs can be used along with lower doses of more expensive medications. With this tandem approach, the infection is kept low and extremely manageable. Having a minimal viral load results in low immune activity and prevents the virus cells from spreading throughout the body. Because of this symptoms are virtually absent. This translates into lower costs for a lifelong regimen of anti-HIV medication, both for the individual patients and for health care systems worldwide.
Life After AIDS
Life After AIDS: A Realistic Timetable
Up until 2001 and the advent of antiretroviral (ART) medications, HIV and AIDS was considered an epidemic, with death almost a certainty. Or, at least this was the case for those who were not wealthy or heavily covered by health insurance. AZT, the first popular antiretroviral drug, was extremely expensive. It was also only available in limited quantities, as manufacturers strained to produce enough of the drug for the needs of the worldwide population. This has all changed. Because of new research, a greater awareness of HIV, and insight into what the virus is and how it works, many scientists and doctors are reasonably hopeful in a future life after AIDS. In fact, some are even creating realistic timetables as to when this could be realized.
There is still no known cure for HIV infection. It is this virus – when left untreated – that causes acquired immune deficiency syndrome (AIDS). There are several drugs available today, however, which can either deactivate HIV cells or kill them outright. Through a regimen of these drugs, a person can survive with HIV for many years, even decades, without ever developing AIDS.
Moreover, this new phase of research into anti-HIV medications has resulted in an outpouring of education and understanding about the virus and disease. Certainly, the stigmas that were once attached to AIDS in the 1980’s have lessened. Because of the new treatments and changing attitudes, many have come forward to be tested who, in the past, might have assumed they would die and didn’t come forward for treatment to avoid the ‘shame’ of being HIV positive. Thanks to this domino effect of research and awareness the number of deaths from AIDS, although still unacceptably high, has been drastically reduced to 3 million per year. It has also led to fewer new infections from HIV, which numbers around 3.5 million per year.
In impoverished countries, those without adequate access to drug therapies, medical facilities, and proper HIV education, the number of deaths to AIDS along with new cases of HIV is still on the rise. This is the biggest hurdle to achieving the lofty goal of a life after AIDS. Even so, with the dramatic results in the past 13 years in countries like the United States, many are hopeful that by the later end of the 21st century, it is possible there will be no new infections. This will only happen when drugs have advanced to the point that they can completely sterilize the virus and when said drugs are accessible to everyone in the world.
HIV Requires Early Treatment
10 years ago
by ADMIN
in HIV Research
HIV Requires Early Treatment: B Cells Are the Key in Infected Subjects
It was very clear early on in HIV research that the earlier treatment for the disease begins, the better a person will respond to the antiretroviral medications. However, the exact reason for this has eluded researchers. A recent study of the blood of nearly 100 treated and untreated HIV-infected volunteers has provided a possible explanation as to why HIV requires early treatment. The study underscored the need to begin treatment as close to viral exposure as possible, as it not only means saved lives but it also can ensure a healthier and better quality of life for those living with HIV.
B cells are immune system cells that produce antibodies to viruses like HIV. However, in the above mentioned study, some previously unknown characteristics of B cells were discovered. The researchers found that the antibodies the B cells produced in infected but untreated people were abnormal. These B cells were more activated, more unstable and unresponsive to further stimulation as compared to normal B cells. This may explain why HIV antibodies naturally produced in the body are unable to clear the infection.
The research further discovered that those who were HIV infected—but had undergone early antiretroviral treatment—had B cell responses that were dramatically different from those who had not received treatment. In the treated patients their antibodies were normal, although there were less of them than in the untreated volunteers. The treated patient’s antibodies were also stronger and more effective on the HIV cells. This resulted in a lower amount of virus in the blood, known as a viral load. It also meant a low level of immune activation, which results in a stronger and healthier immune system. All of this underscores the fact that HIV requires early treatment. Antiretroviral medication, when prescribed during the early stages of the infection can stabilize the mutation of any cells – T cells or B cells. This means that the infected person’s natural immune defenses will be robust and better able to defend against HIV for the long run.
New HIV Antibody
10 years ago
by ADMIN
in HIV Therapy
New HIV Antibody: Reveals New HIV Vulnerability
It has recently been discovered that a new HIV antibody, known as 35O22, binds itself to a spot on the HIV cell walls—one that was not previously recognized as a vulnerable location. This viral spike, which is located in an area straddling the proteins gp41 and gp120, is weak to the antibody. Because of this, 35O22 is able to bind to the HIV cell and actually neutralizes several strains of the virus. This new HIV antibody has many researchers cautiously hopeful, as the discovery could turn out to be extremely significant.
Over half of the known HIV strains, roughly 60 percent, are affected by the 35O22 antibody. In laboratory tests, moreover, the antibody actually prevented these strains of HIV from infecting other cells. More good news is that the antibody is very potent, which means only a small amount of the antibody is needed to neutralize the virus. After discovering 35O22, scientists and researchers have identified other 35O22-like antibodies that are common in groups of HIV-infected people. Indeed, their blood contains antibodies that could potentially neutralize most of the known HIV strains. This suggests that a vaccine could elicit 35O22 much easier than other less common bNAbs (Broadly Neutralizing HIV-1 Antibodies) – the grouping of antibodies 35O22 belongs in.
Researchers also report that the strains of HIV that 35O22 neutralizes compliments the strains neutralized by other bNAbs. This means that combining 35O22 with some of the other bNAbs in a vaccine, prevention treatment, or therapy could produce a single solution to the problem of HIV: the complete neutralization of the vast majority of HIV strains found around the globe. This new HIV antibody and the exposure of a new vulnerability in the HIV cell is therefore very significant. In fact, it could mean a potential cure for HIV by way of preventing all known strains of the virus from replicating.
Computers Against HIV
10 years ago
by ADMIN
in HIV Science
Computers Against HIV: A Striking Ally
Research into eliminating HIV and AIDS has always been a battle against time. Certain compounds that were once successful in destroying the virus cells, or in causing them to become sterile or inefficacious, are now worthless against the virus. This is a direct result of the ability of HIV to constantly mutate and adapt. Thus, new compounds are continually needed, and new methods of treatment are constantly sought after. One group of researchers, based at the University of Southern Denmark, are exploring methods that would accelerate the very process of finding new compounds that can be used against the HIV cells. What they’ve successfully done is to use computers to find potential compounds against HIV—at a rate magnified by several hundred percent! It might be said, then, that the use of computers against HIV has enlisted a formidable new ally in the war against HIV.
The problem is not the lack of compounds that have the potential to destroy or effectively stop the HIV cells. These days, scientists are able to reproduce almost anything imaginable in their laboratories. The problem is to effectively find and identify those compounds. By using computers based on quantum physics – which speed up processing times by several fold – the researchers at USD were able to pinpoint compounds that have varied effects on the HIV cells.
Many of these compounds do not kill the cells outright but, instead, stop HIV cells from being able to reproduce. ‘HIV is a retrovirus that contains enzymes which make it able to copy itself with the help of host genetic material and thus reproduce. If you can block these enzymes’ ability to replicate itself, the virus cannot reproduce.’ This is according to Vasanthanathan Poongavanam, a member of the research team at Southern Denmark. The group was able to identify 25 promising compounds. When the 25 compounds were then tested using the group’s advanced computer systems the field was narrowed to 14, which inhibited the virus’s ability to reproduce. ‘It took us only a few weeks to find these 14 very interesting compounds, whereas before it would have taken years.’ All of this illustrates that using computers against HIV has brought a daunting new player onto the field.
